Analysis of the Influencing Factors of Neurological Toxicity Associated with Oxaliplatin

OBJECTIVE To discuss the incidence and influencing factors of oxaliplatin related neurological toxicity and provide reference for prevent of the oxaliplatin related neurological toxicity. METHODS It was a retrospective study of inpatients treated with chemotherapy by oxaliplatin. To collect the data of incidence rate of the oxaliplatin related neurological toxicity, general condition of the inpatients, monitored value of blood-biochemistry and the circumstance of adjuvant medicines. Compared the intergroup difference between the 2 groups of patients who occurred the oxaliplatin related neurological toxicity or no by statistics analysis, and observed the index by logistic regression analysis to investigate the risk of factors in oxaliplatin related neurological toxicity. RESULTS It contained a total of 1?216 valid cases. Oxaliplatin related neurological toxicity occurred in 817 cases(67.19%). Compared the 2 groups of patients who occurred Oxaliplatin related neurological toxicity or no,the results showed that the clinical diagnoses, staging of disease, body surface area, number of chemotherapy, retained drug dose, and the numerical value of the white blood cell count, lymphocytic count, thrombocyte count, calcium ion which were changed before and after chemotherapy, and whether complicated with Calcium/magnesium(Ca/Mg) mixtures. Twelve indicators had a statistically significant difference between the 2 group (P<0.05). Observed indexes of the P<0.05 by logistic regression analysis, the results showed that the numerical value variation of thrombocyte count, staging of disease, retained drug dose were the influence factors of oxaliplatin related neurological toxicity thrombocyte count before and after chemotherapy. CONCLUSION It is a high level of the incidence of oxaliplatin related neurological toxicity, which should be payed enough attention．Especially the patiens who change of the numerical value of thrombocyte count has been momentous, later of the staging of disease, high level of the retained drug dose should be frequently monitored the clinical manifestation of the oxaliplatin related neurological toxicity, and take withdrawal or symptomatic treatment when necessary.